Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 82 clinical trials
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Study of Intravenous ZMA001 in Healthy Subjects

Background A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made …

18 - 60 years of age Both Phase 1
C Curtiss Stinis, MD

Evaluating Infrasonic Hemodynography

This comparative diagnostic accuracy study will determine the accuracy of a noninvasive wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of the cardiovascular system.

- 100 years of age Both Phase N/A

Peripheral Nerve Blocks for Above-the-knee Amputations

Surgery performed with nerve blocks and sedation may be safer and provide better pain control compared to general anesthesia and opioid therapy in high-risk patient populations such as elderly and troubled with peripheral vascular disease, diabetes, hypertension, coronary artery disease, and chronic obstructive pulmonary disease (COPD).

18 - 100 years of age Both Phase 4

COMPERA / COMPERA-KIDS

In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the …

1 - 100 years of age Both Phase N/A
Z Zhihong Liu, MD,PhD

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to …

18 - 100 years of age Both Phase N/A
S Shaoliang Chen, MD

National Registry and Cohort Study of Pulmonary Vascular Disease

This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH;also to set up registration system of PH in China, to build a database of Chinese PH, to establish a …

- 100 years of age Both Phase N/A
E Erika Rosenzweig, MD

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is …

1 - 21 years of age Both Phase N/A
G Grzegorz Kopeć

DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL

The BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland. All patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension confirmed in right heart catheterization, will be eligible to participate in the …

3 - 100 years of age Both Phase N/A
A Amresh Raina, MD

Pulmonary Hypertension Association Registry

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people …

- 100 years of age Both Phase N/A

Hormonal, Metabolic, and Signaling Interactions in PAH

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

- 90 years of age Both Phase N/A

Rewrite in simple language using AI